The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Oncologist Survey Suggests Traditional Drugstores Lack Expertise With Specialty Medications
December 13th 2013Oncologists and other specialists who prescribe specialty medications are highly satisfied with their specialty pharmacy, but that satisfaction doesn't translate to some traditional drugstores.
Wake Forest Baptist More Than Doubles Cancer Center Size, Adds More Providers
December 9th 2013To respond to the growing demand in cancer services that the existing cancer center was experiencing, Wake Forest Baptist Medical Center is expanding its comprehensive cancer center to help patients cope with the daunting challenges of cancer diagnosis and treatment.
Oncology Group Uses ASCO Metrics for Physician Compensation Program
November 26th 2013The hematology-oncology division of an academic health center participated in a pilot physician compensation exercise using variable compensation incentives with group-specific targets based on prior below-average performance.
Early Data Show Patients With STS May Benefit From Belinostat
November 26th 2013Final results from the first stage of the phase II portion of the phase I/II CLN-14 clinical trial analyzing belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS) demonstrated that the novel agent could provide benefit in this space
New Oncology Consortium Developing Guidance Policies for Payers
November 25th 2013A new consortium of payers, clinicians, patients, and pharmaceutical companies are developing recommendations to help generate evidence-based guidelines to define coverage and develop payment decisions for treating cancer.
Aldoxorubicin More Effective Than Doxorubicin in Soft Tissue Sarcomas
November 22nd 2013Aldoxorubicin (formerly INNO-206) has demonstrated response rates that culminated in a higher incidence of stable disease when compared to doxorubicin as a first-line treatment for patients with advanced soft tissue sarcomas.
Eribulin Shows Promise in Pediatric Sarcomas
November 21st 2013Eribulin has demonstrated a high level of antitumor activity that was equivalent or superior to vincristine across several sarcoma xenograft models, including at low dose levels, suggesting the drug may effectively treat pediatric patients with sarcoma.
ThyroSeq Test Could Reduce Unnecessary Surgeries for Thyroid Cancer
November 20th 2013A new test has been developed to identify the difference between malignant and benign nodules in the thyroid gland, which could potentially reduce the number of unnecessary surgeries, according to an announcement from The University of Pittsburgh Schools of the Health Sciences.
Treating Renal Cell Carcinoma in 2013: An Interview With Sumanta Kumar Pal, MD
November 19th 2013Over the past few years, seven new drugs have gained approval from the FDA for the treatment of patients with metastatic renal cell carcinoma. Primarily these approaches target angiogenesis and mTOR. The advent of these molecularly targeted therapies has significantly improved the standard of care for patients with RCC.
In Treatment Discussions With Oncologists, Patients Ask 'How Much?'
November 19th 2013Two studies presented at this year's ASCO meeting suggest that a significant proportion of patients with cancer want to include the cost of therapy in their discussion of treatment options with their physician, regardless of insurance coverage.
MK-3475 Efficacy Expanded With Longer Follow-Up in Melanoma
November 18th 2013The investigational anti-PD-1 immunotherapy MK-3475 has demonstrated an overall survival rate of 81% at one year in patients with advanced melanoma, according to additional data from a phase Ib clinical trial presented at the 10th International Congress of the Society for Melanoma Research in Philadelphia.
IOM Issues Recommendations to Improve Cancer Care Delivery
November 15th 2013Delivering high-quality cancer care continues to be a daunting problem for the US healthcare system because of a combination of factors, including an aging population, a shrinking work force, the rising cost of therapies, and a complex disease state and treatment regimen.
Drugs and Biologics Account for Largest Practice Expenses
November 13th 2013The highest expense reported by community oncology practices continues to be attributable to drugs and biologics, according to "2013 Trends in Community Cancer Centers," a survey sponsored by the Association of Community Cancer Centers.
Everolimus Offers Benefit in Papillary Renal Cell Carcinoma
November 13th 2013Everolimus provides clinical benefit to patients with papillary metastatic renal cell carcinoma, offering promising overall survival results and a tolerable side-effect profile, investigators found in a study presented during the 2013 European Cancer Congress in Amsterdam.
How One Oncology Practice Took Advantage of Economies of Scale
November 12th 2013One oncology practice in Florida seems to have been able to adapt its practice model, taking advantage of economies of scale, and identifying new revenue streams, while still providing quality care and keeping its oncologists satisfied professionally.